ERBB2 and glioma: Overexpression of RICTOR was also observed in gliomas with high Akt activity in nearly 70% of patients and HER2 (human epidermal growth factor receptor-2)-positive breast cancers, leading to Akt hyperactivity and tumor aggravation [72,74].